Filing excerpt
We anticipate that our cash from operations, together with our current borrowing capacity, will be sufficient to fund... our capital expenditure program costs, which are expected to be approximately $130.0 in 2026 including manufacturing capacity investments for THERABREATH® and Sterimar and an enterprise resource planning (ERP) project.